APA (7th ed.) Citation

PH, C., & H, F. (2025). CRF1 and ACTH inhibitors are a promising approach to treat obesity and leptin and insulin resistance. Frontiers in endocrinology, 16, 1647028. https://doi.org/10.3389/fendo.2025.1647028

Chicago Style (17th ed.) Citation

PH, Contreras, and Falhammar H. "CRF1 and ACTH Inhibitors Are a Promising Approach to Treat Obesity and Leptin and Insulin Resistance." Frontiers in Endocrinology 16 (2025): 1647028. https://doi.org/10.3389/fendo.2025.1647028.

MLA (9th ed.) Citation

PH, Contreras, and Falhammar H. "CRF1 and ACTH Inhibitors Are a Promising Approach to Treat Obesity and Leptin and Insulin Resistance." Frontiers in Endocrinology, vol. 16, 2025, p. 1647028, https://doi.org/10.3389/fendo.2025.1647028.